Nucleic acid-triggered tumoral immunity propagates pH-selective therapeutic antibodies through tumor-driven epitope spreading

Cancer Sci. 2023 Jan;114(1):321-338. doi: 10.1111/cas.15596. Epub 2022 Oct 17.

Abstract

Important roles of humoral tumor immunity are often pointed out; however, precise profiles of dominant antigens and developmental mechanisms remain elusive. We systematically investigated the humoral antigens of dominant intratumor immunoglobulin clones found in human cancers. We found that approximately half of the corresponding antigens were restricted to strongly and densely negatively charged polymers, resulting in simultaneous reactivities of the antibodies to both densely sulfated glycosaminoglycans (dsGAGs) and nucleic acids (NAs). These anti-dsGAG/NA antibodies matured and expanded via intratumoral immunological driving force of innate immunity via NAs. These human cancer-derived antibodies exhibited acidic pH-selective affinity across both antigens and showed specific reactivity to diverse spectrums of human tumor cells. The antibody-drug conjugate exerted therapeutic effects against multiple cancers in vivo by targeting cell surface dsGAG antigens. This study reveals that intratumoral immunological reactions propagate tumor-oriented immunoglobulin clones and demonstrates a new therapeutic modality for the universal treatment of human malignancies.

Keywords: (14) characteristics and pathology of human cancer; humoral immunity; immune repertoire; pH-selective antibody; sulfated glycosaminoglycan; tumor-infiltrating B cell.

MeSH terms

  • Antibodies
  • Antigens
  • Antigens, Surface
  • Epitopes
  • Humans
  • Hydrogen-Ion Concentration
  • Neoplasms* / therapy
  • Nucleic Acids*

Substances

  • Epitopes
  • Nucleic Acids
  • Antigens
  • Antibodies
  • Antigens, Surface